For Grant Nerren, 2025 was a busy year, full of highs and lows that likely contributed to a certain level of stress. Life was ...

Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

A new national survey from the Bladder Cancer Advocacy Network (BCAN) finds that many bladder cancer patients still face major gaps in diagnosis, mental health support and financial protection, ...

J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as ...

ONE in 10 A&E patients who complain of a common bladder cancer symptom die within just three months, concerning research suggests. Bladder cancer is one of the most common cancers in ...

India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten accident and emergency patients (A&E patients) with visible blood in urine ...

Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning sign. Researchers analyzing millions of medical records found that people ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

Seeing blood in urine is often the first clue that something is wrong. For many people, noticing this symptom prompts a medical visit that can lead ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Researchers at Fondazione Policlinico Universitario Agostino Gemelli IRCCS have developed a promising machine learning algorithm capable of predicting survival and cause of death for patients with ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...